Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 263-273

  Prasad, Preethy ^a   Shuhendler, Adam ^a   Cai, Ping ^a   Rauth, Andrew M ^b   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Anti angiogenesis; Doxorubicin; Efficacy; Mitomycin C; Nanoparticles; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; CD31 ANTIGEN; CREATINE KINASE; DOXORUBICIN; LACTATE DEHYDROGENASE; LIPOSOME; MACROGOL STEARATE; MITOMYCIN; MYRISTIC ACID; NANOPARTICLE; POLYMER; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; LIFESPAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPIDS; MICE; MICE, NUDE; MITOMYCIN; NANOPARTICLES; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; STEARATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 84878222030     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.008     Document Type: Article

References (70)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. N. Howlader, A.M. Noone, M. Krapcho et al., SEER Cancer Statistics Review, National Cancer Institute, Bethesda, MD, 1975-2008.
3. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 2007, 608:1-22.
4. Alvarez R.H. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010, 12:S1.
5. Cummings J., Willmott N., Hoey B.M., Marley E.S., Smyth J.F. The consequences of doxorubicin quinone reduction in vivo in tumour tissue. Biochem. Pharmacol. 1992, 44:2165-2174.
6. Cutts S.M., Swift L.P., Rephaeli A., Nudelman A., Phillips D.R. Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol. Cancer Ther. 2003, 2:661-670.
7. Pommier Y., Leo E., Zhang H. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17:421-433.
8. Smith L.A., Cornelius V.R., Plummer C.J. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337-351.
9. Chatterjee K., Zhang J., Honbo N., Karliner J.S. Doxorubicin cardiomyopathy. Cardiology 2010, 115:155-162.
10. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99(19):1441-1454.
11. Solyanik G.I. Multifactorial nature of tumor drug resistance. Exp. Oncol. 2010, 32(3):181-185.
12. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007, 446:749-757.
13. Wong H.L., Wu X.Y., Bendayan R. Multidrug resistance in solid tumors and its reversal. Pharmaceutical Perspectives of Cancer Therapeutics 2007, 121-148. Springer, New York. Y. Lu, R.I. Mahato (Eds.).
14. Trédan O., Galmarini C.M., Patel K., Tannock Ian F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
15. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 2004, 1:27-42.
16. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP dependent transporters. Natl. Rev. Cancer 2003, 2:48-58.
17. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLNs) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Rel. 2006, 116:275-284.
18. Wong H.L., Rauth M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., Erhan S.Z., Wu X.Y. A new solid lipid nanoparticle formulation increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 2006, 23:1574-1585.
19. Shuhendler A.J., Cheung R.Y., Manias J., Connor A., Rauth A.M., Wu X.Y. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 2010, 119:255-269.
20. Abdekhodaie M.J., Liu Z., Erhan S.Z., Wu X.Y. Characterization of novel soybean-oil-based thermosensitive amphipilic polymers for drug delivery applications. Polym. Int. 2012, 10.1002/pi.4244.
21. Prasad P., Cheng J., Shuhendler A., Rauth A.M., Wu X.Y. A novel nanoparticle formulation overcoming multiple multidrug efflux pumps in human breast cancer. Drug Deliv. Transl. Res. 2012, 2:95-105.
22. Shuhendler A.J., O'Brien P., Rauth A.M., Wu X.Y. On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. Drug Metab. Drug Interact. 2008, 22:201-233.
23. Cheung R.Y., Rauth A.M., Wu X.Y. In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations. Anticancer Drugs 2005, 16:423-433.
24. Tomsaz M., Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Phamacol. Ther. 1997, 76:73-87.
25. Mitomycin Monograph, in: G.K. McEvoy (Ed.), American Hospital Formulary Service. American Society of Health System Pharmacists Inc., Bethesda, 2003. pp. 1085-1088.
26. Bradner W.T. Mitomycin C: a clinical update. Cancer Treat. Rev. 2001, 27:35-50.
27. http://clinicaltrials.gov/ct2/results?term=mitomycin+for+cancer.
28. Fukumura D., Duda D.G., Munn L.L., Jain R.K. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010, 17(3):206-225.
29. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63(3):136-151.
30. Zamboni W.C. Liposomal, nanoparticle and conjugated formulations of anticancer agents. Clin. Cancer Res. 2005, 11:8230-8234.
31. Egusquiaguirre S.P., Igartua M., Hernandez R.M., Pedraz J.L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin. Trans. Oncol. 2012, 14(2):83-93.
32. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
33. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 2010, 12:2569-2589.
34. Obrien M.E., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caleyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15(3):440-449.
35. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
36. Harris L., Batist G., Belt R., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicentre trial as first line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36.
37. Charrois G.J., Allen T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004, 1663:167-177.
38. Lyass O., Uziely B., Ben-Yosef R., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
39. Uziely B., Jeffers S., Isacson R., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995, 13:1777-1785.
40. Lotem M., Hubert A., Lyass O., et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. 2000, 136:1475-1480.
41. Shuhendler A.J., Prasad P., Chan H.C., Gordijio C.R., Soroushian B., Kolios M., Yu K., O'Brien P., Rauth A.M., Wu X.Y. Hybrid quantum dot-fatty ester stealth nanoparticles: towards clinically relevant in vivo optical imaging of deep tissue. ACS Nano 2011, 5:1958-1966.
42. A.J. Shuhendler, P. Prasad, M. Leung, A.M. Rauth, R.S DaCosta, X.Y. Wu, Cyclic RGD as a double-edged sword: active targeting of solid lipid nanoparticles to tumor vasculature-associated αvβ3 integrin receptor, Adv. Healthcare Mater., (2012) . http://dx.doi.org/10.1002/adhm.201200006.
43. Lee K.A., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. PNAS 2009, 106:2353-2358.
44. Ramsay E.C., Anantha M., Zastre J., Meijs M., Zonderhuis J., et al. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin. Cancer Res. 2008, 14:1208-1217.
45. Chou T.C., Dong H., Zhang X., Tong W.P., Danishefsky S.J. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route. Cancer Res. 2005, 65:9445-9454.
46. Monsky W.L., Carreira C.M., Tsuzuki Y., Gohongi T., Fukumura D., Jain R.K. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res. 2002, 8:1008-1013.
47. Richmond A., Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis. Model Mech. 2008, 1:78-82.
48. Leonessa F., Green D., Licht T., Wright A., Wingate-Legette K., Lippman J., Gottesman M.M., Clarke R. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br. J. Cancer 1996, 73:154-161.
49. Lake D.E., Hudis C.A. High-dose chemotherapy in breast cancer. Drugs 2004, 64:1851-1860.
50. Krishna R., St-Louis M., Mayer L.D. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int. J. Cancer 2000, 85:131-141.
51. Menezes D.L., Hu Y., Mayer L.D. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. J. Exp. Ther. Oncol. 2003, 3:72-82.
52. Jiang J., Yang S.J., Wang J.C., Yang L.J., Xu Z.Z., Yang T., Liu X.Y., Zhang Q. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur. J. Pharm. Biopharm. 2010, 76:170-178.
53. Xiong X.B., Ma Z., Lai R., Lavasanifar A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 2010, 31:757-768.
54. Shahi P.K., Lovelle A.S., Manga G.P. Tumoral angiogenesis and breast cancer. Clin. Transl. Oncol. 2009, 11:138-142.
55. Kerbel S. Tumor angiogenesis. New Engl. J. Med. 2008, 358:2039-2049.
56. Linderholm B., Grankvist K., Wilking N., et al. and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 2000, 18:1423-1431.
57. Guidi A.J., Schnitt S.J., Fischer L., Tognazzi K., Harris J.R., Dvorak H.F., Brown L.F. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997, 80:1945-1953.
58. Nieto Y., Woods J., Nawaz F., Baron A., Jones R.B., Shpall E.J., Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br. J. Cancer 2007, 97:391-397.
59. Sweeney C., Sledge G. Chemotherapy agents as antiangiogenic therapy. Cancer Conf. Highlights 1999, 3:2-4.
60. Bocci G., Nicolaou K.C., Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002, 62:6938-6943.
61. Gasparini G. Metronomic scheduling: the future of chemotherapy. Lancet Oncol. 2001, 2:733-744.
62. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
63. Mamidi R.N., Weng S., Stellar S., Wang C., Yu N., Huang T., Tonelli A.P., et al. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?. Cancer Chemother. Pharmacol. 2010, 66:1173-1184.
64. Kassner N., Huse K., Martin H.J., Gödtel-Armbrus U., Metzger A., et al. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab. Dispos. 2008, 36:2113-2120.
65. Koukourakis M.I., Kontomanolis E., Giatromanolaki A., Sivridis E., Liberis V. Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases. Gynecol. Obstet. Invest. 2009, 67:162-168.
66. Ozer J., Ratner M., Shaw M., Bailey W., Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245:194-205.
67. Kehla D.W., Iqbalb N., Fardb A., Kipperb B.A., Landab A.P., Maisela A.S. Biomarkers in acute myocardial injury. Transl. Res. 2012, 159:252-264.
68. Laverman P., Carstens M.G., Boerman O.C., Dams E.T., Oyen W.J., van Rooijen N., Corstens F.H., Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther. 2001, 298:607-612.
69. Ishida T., Masuda K., Ichikawa T., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm. 2003, 255:167-174.
70. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 2006, 112:15-25.